BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 26188014)

  • 1. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics.
    Weeks J; Strom AI; Widjaja V; Alexander S; Pucher DK; Sohl CD
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34065652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
    Ohba S; Hirose Y
    Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of glioma and IDH1/IDH2 mutations.
    Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
    Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
    Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
    J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
    Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
    Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
    Zhang C; Moore LM; Li X; Yung WK; Zhang W
    Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive in vivo assessment of IDH1 mutational status in glioma.
    Chaumeil MM; Larson PE; Yoshihara HA; Danforth OM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
    Nat Commun; 2013; 4():2429. PubMed ID: 24019001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.
    Schaap FG; French PJ; Bovée JV
    Adv Anat Pathol; 2013 Jan; 20(1):32-8. PubMed ID: 23232569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
    Guo C; Pirozzi CJ; Lopez GY; Yan H
    Curr Opin Neurol; 2011 Dec; 24(6):648-52. PubMed ID: 22002076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-2-Hydroxyglutarate in Glioma Biology.
    Chou FJ; Liu Y; Lang F; Yang C
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of isocitrate dehydrogenase in glioma.
    Alexander BM; Mehta MP
    Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism, gliomas, and IDH1.
    Smeitink J
    N Engl J Med; 2010 Mar; 362(12):1144-5. PubMed ID: 20335593
    [No Abstract]   [Full Text] [Related]  

  • 20. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
    Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
    Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.